PHVS · Pharvaris N.V. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on PHVS. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About PHVS · Pharvaris N.V.
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Live Quote
BUY (score +8) · 12-1 mom 77.6% · RSI 61.5 · above_both · -0.7% from high
Targets blend Wall Street consensus (13 analysts: low $32.01 / mean $45.50 / high $71.68) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
This investigation was triggered by a cluster of insider Form 4s — 3 in the past 14 days. Upon full verification, every single transaction across all 22 filings returned over the past ~2 months is either (S) = scheduled Rule 10b5-1 plan sale or (F) = tax-withholding share cancellation. Zero open-market P-code purchases exist anywhere in this company's SEC history. The recent filing cluster represents normal option-exercise-and-sell events, not discretionary insider conviction. Combined with a $132M equity offering that just closed (dilution), no upcoming earnings date, and options chain illiquidity making premium collection unreliable for income strategies, there is simply no anomaly here in any direction the pipeline can monetize.